Introduction
============

A number of recent randomized, double-blind clinical trials in neuropathic pain have failed to demonstrate a significant difference between active treatment and placebo, despite previous positive results.[@b1-jpr-8-257]--[@b4-jpr-8-257] At the same time, many recent studies in this patient population have had high placebo-response rates.[@b5-jpr-8-257],[@b6-jpr-8-257] The placebo effect is known to be particularly high for analgesics,[@b7-jpr-8-257] and it has been widely suggested that the higher placebo response may have contributed to the difficulty in discerning a positive treatment effect in recent trials.[@b1-jpr-8-257],[@b8-jpr-8-257]

The pregabalin neuropathic pain database offers a unique opportunity to study the placebo response across clinical trials with the same drug and a similar trial design. This is the first analysis specifically investigating the placebo response and its predictors in clinical trials of pregabalin in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN). In this report, we present the results of univariate and multivariate analyses and comparisons between pregabalin studies in DPN and PHN in which there was a high placebo response with studies in which there was a low placebo response, in an attempt to identify aspects of study design and patient characteristics that may contribute to the placebo response.

Identifying factors associated with a higher placebo response could help investigators design clinical trials that result in lower placebo-response rates, potentially increasing the sensitivity and accuracy of efficacy measures in these trials.[@b9-jpr-8-257]

Material and methods
====================

Study design and patient population
-----------------------------------

For this analysis, patient-level data were pooled from 16 randomized, placebo-controlled, parallel-group, double-blind trials of pregabalin for the treatment of DPN or PHN, all sponsored by Pfizer Inc. and approved by relevant institutional review boards ([Table 1](#t1-jpr-8-257){ref-type="table"}). Of these, nine trials were in patients with DPN, five were in PHN, and two were in mixed populations of DPN and PHN patients. DPN and PHN data were analyzed individually and combined. Studies were conducted in centers in Asia, Australia, Canada, Europe, Latin America, the Middle East, South Africa, and the United States. The study lengths ranged from 5 to 14 weeks, and doses of pregabalin ranged from 75 to 600 mg/day. In those studies with flexible dosing, pregabalin was escalated in doses of 150, 300, 450, and 600 mg/day and titrated in weekly intervals based on patient's individual response and tolerability. Trials included are identified by study number: 1008-014,[@b10-jpr-8-257] 1008-029,[@b11-jpr-8-257] 1008-030,[@b12-jpr-8-257] 1008-040,[@b12-jpr-8-257] 1008-045,[@b13-jpr-8-257] 1008-155,[@b14-jpr-8-257] 1008-127,[@b15-jpr-8-257] 1008-131,[@b16-jpr-8-257] 1008-149,[@b17-jpr-8-257] 1008-196,[@b18-jpr-8-257] A0081004 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT00159666),[@b19-jpr-8-257] A0081030 (NCT00156078), A0081060 (NCT00159679),[@b20-jpr-8-257] A0081071 (NCT00143156), A0081081 (NCT00301223),[@b21-jpr-8-257] and A0081163 (NCT00553475).[@b22-jpr-8-257] Primary data from studies 1008-040 (conducted in 49 centers in ten countries across Europe, Australia, and South Africa), A0081030 (conducted in 47 centers in 19 countries across Asia, Europe, Latin America, and the Middle East), and A0081071 (conducted in 50 centers in the United States) are reported here for the first time.

Key entry criteria included the following: at least 18 years of age; primary diagnosis of either DPN (type 1 or 2 diabetes with painful, distal, symmetrical, or sensorimotor polyneuropathy) or PHN (pain present for ≥3 months after healing of the herpes zoster skin rash); and mean baseline pain score at least 4, as measured on an 11-point numeric rating scale (NRS; where 0= no pain and 10= worst possible pain), for 4 or more days during the week prior to randomization or pain score of at least 40 mm on the 100 mm visual analog scale of the Short-Form McGill Pain Questionnaire[@b23-jpr-8-257] at screening and randomization.

Patients were excluded if they suffered from any neurological disorders or had severe pain unrelated to DPN or PHN that could confound assessment of pain. Patients with DPN were required to discontinue all analgesic medications. Medications that could affect painful symptoms of DPN were prohibited, with the exception of acetaminophen (≤3--4 g/day), aspirin (≤325 mg/day for myocardial infarction or transient ischemic attack prophylaxis), and serotonin reuptake inhibitors (no dose changes 30 days prior to or during the study). Patients with PHN were permitted to continue treatment if they were on a stable regimen of analgesics, anti-inflammatories, or antidepressants. The primary endpoint in all studies was change in endpoint mean pain score, defined as the last seven daily pain score entries (scored on an 11-point NRS) for pregabalin versus placebo.

Statistical analysis
--------------------

Data for the last observation carried forward mean reduction in pain score at endpoint in each trial were analyzed for each group. Trials in which there was a \>2-point mean reduction in pain score in the placebo arm at endpoint were designated "high placebo response," whereas those with a mean reduction of ≤2 points in the placebo arm were designated "low placebo response." A 2-point mean change was selected because this degree of improvement is generally considered to be clinically meaningful in patients with chronic pain.[@b24-jpr-8-257] High placebo-response and low placebo-response trials were pooled and compared with respect to patient and study characteristics. Separately, trials in which there was a \>1.5-point mean change in pain score were compared with those with a ≤1.5-point change. As the placebo response in PHN trials was typically lower than in DPN trials, with no PHN trials having a 2-point mean change, the 1.5-point mean change analysis was conducted in order to compare those PHN trials with a higher response to those with a lower response. A univariate analysis of patient-level data was performed to identify predictors of change in pain score in the placebo group. Categorical variables were analyzed using a chi-square-based method and continuous variables were analyzed using analysis of variance. The relationship between pain scores and secondary efficacy endpoints, Patient Global Impression of Change (PGIC), and sleep interference (by 11-point NRS) in the placebo group were also assessed using an initial test of independence (which strongly rejected the hypothesis that being a placebo pain responder was independent of being a PGIC or sleep responder) followed by calculating the probability that a placebo pain responder would also be a PGIC responder and that a placebo pain responder would also be a sleep responder. A multivariate classification and regression-tree analysis of factors potentially contributing to the placebo response in individual patients was also conducted.

Results
=======

Primary efficacy outcomes
-------------------------

This analysis included 16 studies in which a total of 4,513 patients received ≥1 dose of treatment (2,999 pregabalin and 1,514 placebo). This included 3,053 patients with DPN (2,015 pregabalin and 1,038 placebo) and 1,460 with PHN (984 pregabalin and 476 placebo). Results for the primary efficacy outcome (mean pain score at final assessment compared with baseline) for each study are shown in [Table 2](#t2-jpr-8-257){ref-type="table"}. The two studies conducted in patients with DPN or PHN (1008-155 and A0081081) were each split and examined as DPN patients only and PHN patients only (resulting in 18 total studies included).

Full details of these studies are available in the literature,[@b10-jpr-8-257],[@b11-jpr-8-257],[@b13-jpr-8-257]--[@b22-jpr-8-257] with the exception of studies A0081030, A0081071, and, in part, 1008-040, which are reported here for the first time. In study A0081030, there was no significant difference in mean pain score at endpoint with flexible-dose pregabalin (150--600 mg/day) compared with placebo. In study A0081071, there was also no significant difference in mean pain score at endpoint with pregabalin (300 or 600 mg/day) compared with placebo. In study 1008-040, while there was no significant difference in mean pain score at endpoint with pregabalin 600 mg/day, amitriptyline 75 mg/day significantly improved pain score (least squares mean difference from placebo, −0.93; 95% confidence interval, −1.65 to −0.22; *P*=0.0110). In each of these studies, safety and tolerability were comparable to previously reported pregabalin studies.

High and low placebo-response studies
-------------------------------------

Studies A0081030, A0081071, and A0081081 (DPN patients only) were designated as high placebo-response studies (\>2-point mean change in pain score with placebo) ([Figure 1A and B](#f1-jpr-8-257){ref-type="fig"}; [Table 2](#t2-jpr-8-257){ref-type="table"}). All high placebo-response studies were in patients with DPN and all were negative studies, failing to show a significant treatment difference between pregabalin and placebo. In total, six of the 18 studies included in this analysis were negative studies ([Figure 1A and B](#f1-jpr-8-257){ref-type="fig"}; [Table 2](#t2-jpr-8-257){ref-type="table"}). Of the three negative studies designated as low placebo response in this analysis, two were close to the cutoff of a \>2-point mean change in pain score (studies 1008-040, change in pain score of −1.93; and 1008-155 \[PHN patients\], change in pain score of −1.86). The other negative study (1008-030) had a low placebo response (change in pain score of −0.97) but the pregabalin doses in the actively treated group were low (75 and 150 mg/day).

Study design and baseline demographic and clinical characteristics of patients receiving placebo in high placebo-response and low placebo-response studies are shown in [Table 3](#t3-jpr-8-257){ref-type="table"}. High placebo-response compared with low placebo-response studies tended to be of longer duration, to have been conducted postapproval of pregabalin, to have higher ratios of active treatment to control ([Figure 1A--D](#f1-jpr-8-257){ref-type="fig"}), and to include flexible dosing ([Table 1](#t1-jpr-8-257){ref-type="table"}).

No PHN studies were designated high placebo-response studies; however, there were three PHN studies with a \>1.5-point mean reduction in pain score in the placebo arm (1008-155 \[PHN patients\], A0081004, and A0081081 \[PHN patients\]). Compared with PHN studies with a lower placebo response, these studies also tended to include patients with a younger mean age (65.8 versus 71.5 years) and shorter mean duration of PHN (24.9 versus 37.4 months). In addition, two of these three studies were conducted postapproval of pregabalin, and all three had an active treatment to placebo ratio ≥2:1 and included a flexible-dosing arm ([Figure 1B](#f1-jpr-8-257){ref-type="fig"}; [Table 1](#t1-jpr-8-257){ref-type="table"}).

The impact of patient age and sex on the change in mean pain score for high and low placebo-response studies is shown in [Table 4](#t4-jpr-8-257){ref-type="table"}.

Predictors of placebo response
------------------------------

An analysis of univariate predictors of change in pain in pooled placebo arms (across high and low placebo-response studies) is shown in [Table 5](#t5-jpr-8-257){ref-type="table"} for categorical variables and [Table 6](#t6-jpr-8-257){ref-type="table"} for continuous variables. Studies conducted postapproval of pregabalin for the treatment of DPN or PHN had a significantly higher placebo response than those conducted preapproval (*P*\<0.0001 for DPN/PHN studies combined). There was a higher placebo response in females than in males in both DPN and PHN studies (*P*\<0.0001 for DPN/PHN studies combined). DPN studies with a higher ratio of active treatment to control (≥2:1) had a higher placebo response than those with lower ratios (*P*\<0.0001). This difference was not apparent in PHN studies alone but was in DPN/PHN studies combined (−1.60 versus −1.22; *P*\<0.0001).

In both PHN and DPN studies, neither site recruitment numbers nor time of enrollment was associated with a higher placebo response. A higher number of sites per study was associated with a higher placebo response in DPN studies only.

Among the continuous variables assessed ([Table 6](#t6-jpr-8-257){ref-type="table"}), lower age, shorter duration of PHN, higher baseline pain score, and longer study duration were all significantly associated with a higher placebo response in the combined DPN/PHN population (*P*≤0.0002 for each).

Change in pain score with placebo was also associated with a change in other patient-reported outcomes. For a patient receiving placebo classified as a pain responder (≥30% improvement in pain score at endpoint), there was an 82% probability that they would be a sleep responder (≥30% improvement in sleep interference score at endpoint) and a 64% probability that they would be a PGIC responder (symptoms either "very much improved" or "much improved"). Together, there was a 91% probability that a pain responder receiving placebo would be either a sleep responder or a PGIC responder.

[Figure 1C and D](#f1-jpr-8-257){ref-type="fig"} shows the least squares mean change in pain score for placebo groups in each study by week, stratified by ratio of active treatment to placebo, and whether the study was conducted pre- or postapproval.

There has also been a trend toward an increased placebo response over time in these trials ([Figure 2A and B](#f2-jpr-8-257){ref-type="fig"}). In contrast, over the same time period, the response to pregabalin (at doses of 300 mg/day, 600 mg/day, and flexible dosing) has not meaningfully changed. Although the placebo response in studies in patients with PHN was typically less than that in patients with DPN, both sets of patients have shown a similar increase in mean placebo response in clinical trials over time.

A multivariate analysis of factors contributing to placebo response is shown in [Figure 3](#f3-jpr-8-257){ref-type="fig"}. The highest placebo response was in patients who did not discontinue from the study due to lack of efficacy, were in a study conducted postapproval, in patients with DPN, with ≥36 sites, and who remained in the study for ≥83.97% of its duration.

Discussion
==========

To elucidate the factors involved in the placebo response, we analyzed the results of 16 trials of pregabalin in which 1,514 patients received placebo (1,038 with DPN and 476 with PHN). The major findings of the study are as follows: high placebo-response compared with low placebo-response studies tended to 1) be conducted postapproval of pregabalin; 2) have higher ratios of active treatment to control; 3) be of longer duration; 4) increase over time; and 5) be associated with changes in other patient-reported outcomes. There was no relationship to site recruitment numbers or time of enrollment in the study, and, contrary to previous reports,[@b25-jpr-8-257] the placebo response was higher in flexible-dose studies.

The present data strongly support the importance of expectancy on the placebo effect. Awareness that a drug is an approved therapy is likely to enhance patient expectations and all high placebo-response studies in DPN occurred postapproval, whereas two of the three highest placebo-response studies in PHN occurred postapproval. Knowledge of the likelihood of receiving active drug versus placebo also may influence patients' expectations. In the trials in this analysis, patients were typically aware of their probability of receiving active treatment versus placebo. Pooled analyses in depression,[@b26-jpr-8-257] migraine,[@b27-jpr-8-257] and irritable bowel syndrome[@b28-jpr-8-257] all support an inverse relationship between probability of receiving placebo and placebo response.

The present data, with drug to placebo ratios varying from 1:1 to 4:1, lend some support to these earlier studies. In univariate analyses of DPN and PHN, a higher treatment allocation ratio was significantly associated with a higher placebo response. In DPN, the lowest pre- and postapproval placebo responses occurred in studies with a 1:1 allocation, whereas the highest preapproval placebo response in PHN occurred in a trial with a 4:1 ratio. The regression-tree analysis demonstrated that approval status, but not treatment allocation ratio, was a predictor of placebo response. It is possible that expectations regarding treatment efficacy carry greater salience for research patients than expectations of treatment allocation, but this analysis is limited by the availability of only two postapproval PHN studies.

The major determinants of the effect of expectancy on outcome include susceptibility to suggestion, prior experience, learning, cultural perspectives on medical care, investigator--patient relationship, and other psychosocial factors.[@b29-jpr-8-257],[@b30-jpr-8-257] The present data suggest that to increase assay sensitivity and reduce likelihood of false-negative trials, more attention should be devoted to minimizing expectations in clinical trials. Increased awareness of the role played by verbal suggestions and conscious and unconscious signals conveyed during the course of the trial is necessary. Advocacy for the drug should be avoided, and, particularly in the postapproval environment, recruitment strategies and subject--investigator interactions should have an objective, dispassionate quality.

Consistent with other studies,[@b1-jpr-8-257],[@b31-jpr-8-257],[@b32-jpr-8-257] our data show that the placebo response is greater in DPN than PHN studies. Earlier reports suggest that anatomical differences may underlie this observation.[@b1-jpr-8-257] These authors theorized that PHN pathology is more likely to involve central sites implicated in the placebo response, such as the descending pain modulatory network.[@b1-jpr-8-257] However, other possibilities exist. Greater fluctuations in pain levels in patients with DPN than PHN, in part related to metabolic factors, specifically changes in ambient blood glucose, may act as a conditioning stimulus for the placebo response. Amelioration of hypoglycemia or hyperglycemia may also underlie spontaneous improvement in the DPN group. Also, opioids were a permitted concomitant medication in the PHN but not DPN trials. Exogenous opioids could antagonize those mechanisms of the placebo response mediated by endogenous opioids.

Finally, patient characteristics and trial-related factors may be responsible. Substantially more of the DPN studies were conducted postapproval; patients on placebo in DPN studies had a younger mean age (\~59 years) than those in PHN studies (\~70 years), and DPN studies had a longer mean duration (11.5 and 9.1 weeks for high and low placebo-response studies, respectively) than PHN studies (7.0 weeks). Combined DPN/PHN studies, which in part control for these trial-related factors, yield equivocal results. In one (A0081081), patients with DPN had a higher placebo response than patients with PHN (−2.32 versus −1.65) over 9 weeks, whereas in the other (1008-155) there was little difference between DPN and PHN (−1.78 versus −1.86) over 12 weeks.

Remission may underlie a response in the placebo group, particularly in PHN, a disorder that remits spontaneously, particularly in the first 6 months of the disease. The present data, in which a shorter duration of PHN was associated with a greater placebo response, lend some support to this notion. In these studies, patients with pain present for at least 3 months after healing of the herpes zoster skin rash were allowed to enter the trial. These data suggest that extending the duration of pain after the healing of the rash as an entry criterion may help attenuate the placebo response.

This analysis shows that, over time, there has been a trend towards an increased placebo response in pregabalin trials in DPN and PHN, whereas there has been no corresponding change in the response to pregabalin. Pooled analyses of trials in other patient populations have also noted an increase in placebo response over time.[@b5-jpr-8-257]--[@b7-jpr-8-257],[@b26-jpr-8-257],[@b33-jpr-8-257]--[@b35-jpr-8-257] A meta-analysis of 75 trials in major depressive disorder noted a significant positive association between the proportion of patients responding to placebo and the year of publication (increase in the proportion of patients responding to placebo of approximately 7% per decade between 1981 and 2000).[@b33-jpr-8-257] However, a more recent analysis of 96 trials between 1980 and 2005 confirmed the relationship between study year and placebo response with clinician rating but not with patient self-rating scales.[@b36-jpr-8-257] It is not clear why there has been this increase in placebo response over time, but more recent trials tend to be of longer duration and, with clinical trials now being more common, more likely to include younger patients with shorter disease duration. These factors were associated with a greater placebo response in this analysis.

In the present analysis, a higher baseline pain score was associated with a higher placebo response. This has been observed in other analyses of studies in DPN, fibromyalgia, and depression in which, as with this analysis, both negative and positive studies were included.[@b5-jpr-8-257],[@b36-jpr-8-257] Some recent studies have excluded patients with the highest baseline pain scores (to increase the drug--placebo difference).[@b37-jpr-8-257] However, inherent to this and other approaches to increase assay sensitivity by excluding placebo is the unresolved question of whether placebo and drug responses are independent, additive, or interactive, and whether excluding those most likely to respond to placebo also excludes those most likely to respond to active treatment.

There are limitations to this analysis. Only trials of pregabalin were included; therefore, the findings may not be applicable to other interventions. In addition, given the variability in design of the trials included, direct comparisons may not always be appropriate, particularly as only a limited number of the studies analyzed were high placebo-response studies.

A higher placebo response can limit the ability of a trial to discern a significant treatment effect, resulting in a false-negative, failed trial.[@b1-jpr-8-257] Determination of factors that influence patients' responses to placebo may assist in the design of trials that are able to more accurately and sensitively measure a treatment effect. By increasing assay sensitivity, efficacious treatments may be identified more quickly, reducing the number of trials and limiting the exposure of patients to placebo and unproven medications.[@b7-jpr-8-257]
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![Mean change in placebo response at endpoint, by study week and by study completion date.\
**Notes:** Ratio of active treatment to placebo in each trial (total number of patients on active treatment to placebo) for (**A**) diabetic peripheral neuropathy (DPN) and (**B**) postherpetic neuralgia (PHN) studies; The solid vertical line separates those studies that commenced preapproval of pregabalin (to the left of the line) and postapproval of pregabalin (to the right of the line); The dashed horizontal line shows the 2-point mean change in pain score at endpoint; Studies with a \>2-point change (A0081030, A0081071, A0081081 \[DPN patients\]) were designated high placebo-response studies; \*Indicates trials that were negative (those in which there was no significant difference at endpoint between pregabalin and placebo); The least squares mean change in placebo response by study week for (**C**) DPN and (**D**) PHN studies; Study characteristics are shown by color of the line (ratio of active treatment to placebo) and solid or dashed lines (studies conducted pre- and postapproval, respectively); The position of the circles shown with study numbers indicates the last observation carried forward (LOCF) mean change for that study.](jpr-8-257Fig1){#f1-jpr-8-257}

![Mean change in placebo response at endpoint by study completion date.\
**Notes:** Least squares mean change in pain score from baseline at endpoint for all treatment arms by the year the study was completed for (**A**) diabetic peripheral neuropathy (DPN) and (**B**) postherpetic neuralgia (PHN) trials.](jpr-8-257Fig2){#f2-jpr-8-257}

![Regression-tree analysis of placebo response.\
**Notes:** Box-and-whiskers plots showing median change in pain score with interquartile range; The first separation is on the status of the patients; Those who discontinued from the study due to lack of efficacy had the smallest placebo response; Of those who did not discontinue from the study due to lack of efficacy, patients who were from studies conducted preapproval of pregabalin had a lower placebo response; Of those from studies conducted postapproval of pregabalin, patients who had a baseline pain score \<5.54 had a lower placebo response; Of those from studies conducted preapproval of pregabalin, those from postherpetic neuralgia (PHN) studies had a lower placebo response; Of those from diabetic peripheral neuropathy (DPN) studies, patients from studies with \<36 sites had a lower placebo response; Of those from studies with ≥36 sites, patients who remained in the study for \<83.97% of its duration had a lower placebo response; The highest placebo response was in patients who did not discontinue from the study due to lack of efficacy, were in studies conducted postapproval, were patients with DPN, were in studies with ≥36 sites, and those who remained in the study for ≥83.97% of its duration.](jpr-8-257Fig3){#f3-jpr-8-257}

###### 

Comparison of study designs

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                      Disease       Study dates           Design      Treatment[a](#tfn1-jpr-8-257){ref-type="table-fn"}   Ratio[b](#tfn2-jpr-8-257){ref-type="table-fn"}   Number of centers                                                                              
  -------------------------- ------------- --------------------- ----------- ---------------------------------------------------- ------------------------------------------------ ------------------- ----- -------------------------------------------------------------- ----- ----
  1008-014[@b10-jpr-8-257]   DPN           Mar 1998--Mar 1999    1 week      2 week                                               4 week                                           --                  85    150 mg/d (79)\                                                 2:1   29
                                                                                                                                                                                                             600 mg/d (82)                                                        

  1008-029[@b11-jpr-8-257]   DPN           Aug 1998--Jun 1999    1 week      1 week                                               4 week                                           --                  97    75 mg/d (77)\                                                  3:1   45
                                                                                                                                                                                                             300 mg/d (81)\                                                       
                                                                                                                                                                                                             600 mg/d (82)                                                        

  1008-040[@b12-jpr-8-257]   DPN           Sep 1999--Dec 2000    1 week      2 week                                               6 week                                           1 week              81    600 mg/d (86)\                                                 2:1   49
                                                                                                                                                                                                             Amit 75 mg/d (87)[c](#tfn3-jpr-8-257){ref-type="table-fn"}           

  1008-131[@b16-jpr-8-257]   DPN           Dec 1999--May 2000    1 week      --                                                   8 week                                           --                  70    300 mg/d (76)                                                  1:1   25

  1008-149[@b17-jpr-8-257]   DPN           Nov 2000--May 2002    1 week      1 week                                               11 week                                          --                  96    150 mg/d (99)\                                                 3:1   58
                                                                                                                                                                                                             300 mg/d (99)\                                                       
                                                                                                                                                                                                             300/600 mg/d[d](#tfn4-jpr-8-257){ref-type="table-fn"} (101)          

  A0081030                   DPN           Jan 2005--Apr 2006    1 week      6 week                                               6 week                                           1 week              135   150--600 mg/d[e](#tfn5-jpr-8-257){ref-type="table-fn"} (271)   2:1   47

  A0081060[@b20-jpr-8-257]   DPN           Sep 2004--Oct 2005    1 week      1 week                                               12 week                                          --                  85    600 mg/day (82)                                                1:1   23

  A0081071                   DPN           May 2005--May 2007    1--2 week   1 week                                               12 week                                          1 week              151   300 mg/d (153)\                                                2:1   50
                                                                                                                                                                                                             600 mg/d (152)                                                       

  A0081163[@b22-jpr-8-257]   DPN           Oct 2007--Mar 2009    1 week      1 week                                               12 week                                          1 week              135   300 mg/d (134)\                                                1:1   62
                                                                                                                                                                                                             600 mg/d (45)                                                        

  1008-030[@b12-jpr-8-257]   PHN           Oct 1998--Jul 1999    1 week      --                                                   5 week                                           --                  88    75 mg/d (84)\                                                  2:1   29
                                                                                                                                                                                                             150 mg/d (84)                                                        

  1008-045[@b13-jpr-8-257]   PHN           Feb 1999--Jun 2000    1 week      1 week                                               7 week                                           --                  81    150 mg/d (81)\                                                 2:1   53
                                                                                                                                                                                                             300 mg/d (76)                                                        

  1008-127[@b15-jpr-8-257]   PHN           Dec 1999--May 2000    1 week      1 week                                               7 week                                           --                  84    300 mg/d (30)\                                                 1:1   29
                                                                                                                                                                                                             600 mg/d (59)                                                        

  1008-196[@b18-jpr-8-257]   PHN           Nov 2001--Oct 2002    1 week      1 week                                               12 week                                          --                  93    150 mg/d (87)\                                                 3:1   76
                                                                                                                                                                                                             300 mg/d (98)\                                                       
                                                                                                                                                                                                             300/600 mg/d[d](#tfn4-jpr-8-257){ref-type="table-fn"} (90)           

  A0081004[@b19-jpr-8-257]   PHN           Oct 2004--Jun 2006    1 week      --                                                   4 week                                           1 week              90    300 mg/d (88)\                                                 2:1   42
                                                                                                                                                                                                             150--600 mg/d[e](#tfn5-jpr-8-257){ref-type="table-fn"} (92)          

  1008-155[@b14-jpr-8-257]   DPN and PHN   Jul 2001--Dec 2002    1 week      --                                                   12 week                                          --                  65    600 mg/d (132)\                                                4:1   60
                                                                                                                                                                                                             150--600 mg/d[e](#tfn5-jpr-8-257){ref-type="table-fn"} (141)         

  A0081081[@b21-jpr-8-257]   DPN and PHN   Feb 2006--Sept 2007   1 week      --                                                   8 week                                           1 week              102   150--600 mg/d[e](#tfn5-jpr-8-257){ref-type="table-fn"} (206)   2:1   11
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment groups in each study, including number of patients receiving at least one dose of treatment;

ratio of patients receiving active treatment to those receiving placebo;

included an active comparator arm with 87 patients randomized to amitriptyline;

patients received 300 mg/day if creatinine clearance was higher than 30 but 60 mL/min or less, and 600 mg/day if creatinine clearance was higher than 60 mL/min;

escalating doses of 150, 300, 450, and 600 mg/day, titrated in weekly intervals based on patient's individual response and tolerability.

**Abbreviations:** Amit, amitriptyline; DPN, diabetic peripheral neuropathy; PHN, postherpetic neuralgia.

###### 

Primary efficacy outcomes

  Study                                                                                                                   Treatment                                                n[a](#tfn8-jpr-8-257){ref-type="table-fn"}   Endpoint mean pain score, LS mean   Change in pain score from baseline, LS mean (SE)         Treatment difference (pregabalin versus placebo)   
  ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------- ----------------------------------- -------------------------------------------------------- -------------------------------------------------- ----------
  DPN                                                                                                                                                                                                                                                                                                                                                                           
   1008-014[@b10-jpr-8-257]                                                                                               Placebo                                                  82                                           5.55                                −1.16 (0.23)                                             --                                                 --
                                                                                                                          150 mg/d                                                 79                                           5.11                                −1.60 (0.24)                                             −0.44 (−1.08 to 0.20)                              0.1763
                                                                                                                          600 mg/d                                                 82                                           4.29                                −2.42 (0.23)                                             −1.26 (−1.89 to −0.64)                             \<0.0001
   1008-029[@b11-jpr-8-257]                                                                                               Placebo                                                  97                                           5.06                                −1.35 (0.21)                                             --                                                 --
                                                                                                                          75 mg/d                                                  77                                           4.91                                −1.50 (0.24)                                             −0.15 (−0.76 to 0.46)                              0.6267
                                                                                                                          300 mg/d                                                 81                                           3.80                                −2.61 (0.23)                                             −1.26 (−1.86 to −0.65)                             \<0.0001
                                                                                                                          600 mg/d                                                 81                                           3.60                                −2.81 (0.23)                                             −1.45 (−2.06 to −0.85)                             \<0.0001
   1008-040[@b12-jpr-8-257],[b](#tfn9-jpr-8-257){ref-type="table-fn"},[c](#tfn10-jpr-8-257){ref-type="table-fn"}          Placebo                                                  80                                           4.60                                −1.93 (0.27)                                             --                                                 --
                                                                                                                          600 mg/d                                                 86                                           3.96                                −2.57 (0.26)                                             −0.64 (−1.37 to 0.08)                              0.0822
                                                                                                                          Amit 75 mg/d                                             87                                           3.67                                −2.86 (0.25)                                             −0.93 (−1.65 to −0.22)                             0.0110
   1008-131[@b16-jpr-8-257]                                                                                               Placebo                                                  69                                           5.46                                −0.88 (0.28)                                             --                                                 --
                                                                                                                          300 mg/d                                                 75                                           3.99                                −2.35 (0.26)                                             −1.47 (−2.19 to −0.75)                             \<0.0001
   1008-149[@b17-jpr-8-257]                                                                                               Placebo                                                  93                                           4.66                                −1.77 (0.26)                                             --                                                 --
                                                                                                                          150 mg/d                                                 96                                           4.33                                −2.10 (0.26)                                             −0.33 (−0.94 to 0.28)                              0.2849
                                                                                                                          300 mg/d                                                 96                                           4.48                                −1.95 (0.26)                                             −0.17 (−0.79 to 0.43)                              0.5580
                                                                                                                          300/600 mg/d[d](#tfn11-jpr-8-257){ref-type="table-fn"}   98                                           3.69                                −2.74 (0.25)                                             −0.97 (−1.58 to −0.36)                             0.0018
   1008-155                                                                                                               Placebo                                                  46                                           4.86                                −1.78 (0.37)                                             --                                                 --
   (DPN patients)[@b14-jpr-8-257]                                                                                         600 mg/d                                                 94                                           3.55                                −3.09 (0.27)                                             −1.31 (−2.16 to −0.46)                             0.0028
                                                                                                                          150--600 mg/d                                            103                                          3.73                                −2.91 (0.26)                                             −1.13 (−1.97 to −0.29)                             0.0088
   A0081030[c](#tfn10-jpr-8-257){ref-type="table-fn"},[e](#tfn12-jpr-8-257){ref-type="table-fn"}                          Placebo                                                  134                                          3.85                                −2.54 (0.19)[e](#tfn12-jpr-8-257){ref-type="table-fn"}   --                                                 --
                                                                                                                          150--600 mg/d                                            267                                          3.54                                −2.85 (0.14)                                             −0.30 (−0.74 to 0.13)                              0.1700
   A0081060[@b20-jpr-8-257]                                                                                               Placebo                                                  83                                           4.82                                −1.62 (0.25)                                             --                                                 --
                                                                                                                          600 mg/d                                                 80                                           3.54                                −2.90 (0.26)                                             −1.28 (−1.96 to −0.60)                             0.0003
   A0081071[c](#tfn10-jpr-8-257){ref-type="table-fn"},[e](#tfn12-jpr-8-257){ref-type="table-fn"}                          Placebo                                                  149                                          4.16                                −2.32 (0.20)[e](#tfn12-jpr-8-257){ref-type="table-fn"}   --                                                 --
                                                                                                                          300 mg/d                                                 151                                          3.97                                −2.51 (0.20)                                             −0.19 (−0.71 to 0.33)                              0.4744
                                                                                                                          600 mg/d                                                 148                                          3.84                                −2.64 (0.20)                                             −0.32 (−0.85 to 0.20)                              0.4530
   A0081081                                                                                                               Placebo                                                  70                                           3.89                                −2.32 (0.25)[e](#tfn12-jpr-8-257){ref-type="table-fn"}   --                                                 --
   (DPN patients)[@b21-jpr-8-257],[c](#tfn10-jpr-8-257){ref-type="table-fn"},[e](#tfn12-jpr-8-257){ref-type="table-fn"}   150--600 mg/d                                            143                                          3.50                                −2.71 (0.20)                                             −0.39 (−0.92 to 0.14)                              0.1523
   A0081163[@b22-jpr-8-257]                                                                                               Placebo                                                  135                                          4.83                                −1.20 (0.21)                                             --                                                 --
                                                                                                                          300 mg/d                                                 134                                          4.20                                −1.82 (0.21)                                             −0.63 (−1.09 to −0.17)                             0.0075
                                                                                                                          600 mg/d                                                 45                                           4.08                                −1.94 (0.32)                                             −0.74 (−1.39 to −0.09)                             0.0254
  PHN                                                                                                                                                                                                                                                                                                                                                                           
   1008-030[@b12-jpr-8-257],[c](#tfn10-jpr-8-257){ref-type="table-fn"}                                                    Placebo                                                  87                                           5.59                                −0.97 (0.21)                                             --                                                 --
                                                                                                                          75 mg/d                                                  83                                           5.46                                −1.11 (0.21)                                             −0.14 (−0.71 to 0.43)                              0.6361
                                                                                                                          150 mg/d                                                 82                                           5.52                                −1.05 (0.22)                                             −0.07 (−0.64 to 0.50)                              0.7999
   1008-045[@b13-jpr-8-257]                                                                                               Placebo                                                  81                                           6.33                                −0.52 (0.22)                                             --                                                 --
                                                                                                                          150 mg/d                                                 81                                           5.14                                −1.71 (0.22)                                             −1.20 (−1.81 to −0.58)                             0.0002
                                                                                                                          300 mg/d                                                 76                                           4.76                                −2.09 (0.23)                                             −1.57 (−2.20 to −0.95)                             \<0.0001
   1008-127[@b15-jpr-8-257]                                                                                               Placebo                                                  84                                           5.29                                −1.06 (0.24)                                             --                                                 --
                                                                                                                          300/600 mg/d[d](#tfn11-jpr-8-257){ref-type="table-fn"}   88                                           3.60                                −2.75 (0.24)                                             −1.69 (−2.33 to −1.05)                             0.0001
   1008-196[@b18-jpr-8-257]                                                                                               Placebo                                                  93                                           6.14                                −0.53 (0.23)                                             --                                                 --
                                                                                                                          150 mg/d                                                 87                                           5.26                                −1.41 (0.24)                                             −0.88 (−1.53 to −0.23)                             0.0077
                                                                                                                          300 mg/d                                                 98                                           5.07                                −1.60 (0.23)                                             −1.07 (−1.70 to −0.45)                             0.0008
                                                                                                                          300/600 mg/d[d](#tfn11-jpr-8-257){ref-type="table-fn"}   88                                           4.35                                −2.32 (0.24)                                             −1.79 (−2.43 to −1.15)                             0.0001
   1008-155                                                                                                               Placebo                                                  16                                           5.08                                −1.86 (0.71)                                             --                                                 --
   (PHN patients)[@b14-jpr-8-257],[c](#tfn10-jpr-8-257){ref-type="table-fn"}                                              600 mg/d                                                 34                                           3.64                                −3.31 (0.53)                                             −1.45 (−2.95 to 0.06)                              0.0601
                                                                                                                          150--600 mg/d                                            36                                           3.89                                −3.06 (0.49)                                             −1.20 (−2.69 to 0.30)                              0.1147
   A0081004[@b19-jpr-8-257]                                                                                               Placebo                                                  83                                           4.86                                −1.60 (0.21)                                             --                                                 --
                                                                                                                          300 mg/d                                                 81                                           3.86                                −2.60 (0.21)                                             −1.00 (−1.55 to −0.45)                             0.0004
                                                                                                                          150--600 mg/d                                            90                                           3.50                                −2.96 (0.20)                                             −1.36 (−1.90 to −0.83)                             \<0.0001
   A0081081                                                                                                               Placebo                                                  32                                           4.94                                −1.65 (0.42)                                             --                                                 --
   (PHN patients)[@b21-jpr-8-257]                                                                                         150--600 mg/d                                            60                                           3.67                                −2.93 (0.36)                                             −1.28 (−2.15 to −0.41)                             0.0045

**Notes:** Data for each trial are for last observation carried forward;

number of patients in the intent-to-treat population;

study 1008-040 included an active comparator arm of amitriptyline at 75 mg/day;

negative studies were those in which there was no significant difference at endpoint between pregabalin and placebo;

patients received 300 mg/day if creatinine clearance was \>30 but ≤60 mL/min, and 600 mg/day if creatinine clearance was higher than 60 mL/min;

designated as high placebo-response studies.

**Abbreviations:** Amit, amitriptyline; CI, confidence interval; DPN, diabetic peripheral neuropathy; LS, least squares; PHN, postherpetic neuralgia; SE, standard error.

###### 

Patient and study characteristics for the placebo population in high placebo-response and low placebo-response studies

  Patient characteristics                                                       DPN                         PHN
  ----------------------------------------------------------------------------- ------------- ------------- -------------
  Age, mean (SD), y                                                             58.4 (10.1)   59.3 (10.9)   69.9 (10.4)
  Female, n (%)                                                                 190 (53.8)    276 (40.3)    231 (48.5)
  Male, n (%)                                                                   163 (46.2)    409 (59.7)    245 (51.5)
  Baseline pain score, mean (SD)                                                6.3 (1.5)     6.4 (1.5)     6.6 (1.5)
  Duration of NeP, mean (SD), y                                                 3.8 (3.5)     4.2 (3.2)     --
  Duration of DPN, mean (SD), y                                                 4.3 (4.0)     4.9 (3.7)     --
  Duration of PHN, mean (SD), mo                                                --            --            33.8 (36.9)
  **Study characteristics**                                                                                 
  Study duration, mean (SD), wk                                                 11.5 (3.7)    9.1 (3.8)     7.0 (3.3)
  Total site recruitment                                                                                    
   Patients per site, mean (SD)                                                 5.8 (4.2)     3.8 (2.2)     3.7 (2.2)
    ≤5, n (%)                                                                   217 (61.5)    518 (75.6)    367 (77.1)
    6--8, n (%)                                                                 74 (21.0)     157 (22.9)    91 (19.1)
    9--11, n (%)                                                                30 (8.5)      10 (1.5)      18 (3.8)
    ≥12, n (%)                                                                  32 (9.1)      0             0
  Discontinuations, n (%)                                                       63 (100)      115 (100)     100 (100)
   Adverse event                                                                18 (28.6)     34 (29.6)     28 (28.0)
   Lack of compliance                                                           0             7 (6.1)       2 (2.0)
   Lack of efficacy                                                             14 (22.2)     51 (44.3)     45 (45.0)
   Other                                                                        31 (49.2)     23 (20.0)     25 (25.0)
  Pregabalin approval status,[d](#tfn18-jpr-8-257){ref-type="table-fn"} n (%)                               
   Preapproval                                                                  0             467 (68.2)    361 (75.8)
   Postapproval                                                                 353 (100)     218 (31.8)    115 (24.2)
  Ratio of active to control,[e](#tfn19-jpr-8-257){ref-type="table-fn"} n (%)                               
   1:1                                                                          0             287 (41.9)    84 (17.6)
   ≥2:1                                                                         353 (100)     398 (58.1)    392 (82.4)

**Notes:** There were no high placebo-response studies in patients with PHN; Not all studies recorded duration of illness;

pooled placebo patients from studies A0081030, A0081071, and A0081081 (DPN);

pooled placebo patients from studies 1008-014,1008-029, 1008-040, 1008-131, 1008-149, 1008-155 (DPN), A0081060, and A0081163;

pooled placebo patients from studies 1008-030, 1008-045, 1008-127, 1008-155 (PHN), 1008-196, A0081004, and A0081081 (PHN);

pregabalin approval status at the commencement of the study;

ratio of the total number of patients receiving active treatment to patients receiving placebo.

**Abbreviations:** DPN, diabetic peripheral neuropathy; mo, months; NeP, diabetic neuropathic pain; PHN, postherpetic neuralgia; SD, standard deviation; wk, week; y, years.

###### 

Difference in mean change in pain score between pregabalin and placebo groups in high placebo-response and low placebo-response studies stratified by age and sex

  High placebo response[a](#tfn21-jpr-8-257){ref-type="table-fn"}   Difference   Low placebo response[b](#tfn22-jpr-8-257){ref-type="table-fn"}   Difference                                                                    
  ----------------------------------------------------------------- ------------ ---------------------------------------------------------------- ------------ -------------- ------- ----- -------------- ----- -------------- -------
  **DPN**                                                                                                                                                                                                                       
  Age, y                                                                                                                                                                                                                        
   18--52                                                           195          −2.59 (2.23)                                                     98           −2.36 (2.31)   −0.23   319   −2.35 (2.21)   172   −1.80 (2.02)   −0.56
   53--59                                                           194          −2.74 (2.23)                                                     92           −2.02 (2.06)   −0.71   292   −2.54 (2.42)   138   −1.39 (1.99)   −1.15
   60--66                                                           163          −2.98 (2.32)                                                     94           −2.49 (2.00)   −0.49   347   −2.35 (2.20)   191   −1.28 (2.05)   −1.08
   67--89                                                           157          −2.21 (2.25)                                                     69           −2.30 (2.51)   0.10    348   −2.37 (2.48)   184   −1.33 (2.20)   −1.04
  Sex                                                                                                                                                                                                                           
   Female                                                           372          −2.76 (2.33)                                                     190          −2.31 (2.07)   −0.45   516   −2.55 (2.37)   276   −1.54 (2.27)   −1.02
   Male                                                             337          −2.50 (2.19)                                                     163          −2.28 (2.37)   −0.22   790   −2.30 (2.29)   409   −1.38 (1.94)   −0.92
  **PHN[d](#tfn24-jpr-8-257){ref-type="table-fn"}**                                                                                                                                                                             
  Age, y                                                                                                                                                                                                                        
   18--52                                                           --           --                                                               --           --             --      57    −1.66 (2.24)   33    −2.19 (2.29)   0.53
   53--59                                                           --           --                                                               --           --             --      85    −1.76 (2.36)   38    −1.25 (1.54)   −0.51
   60--66                                                           --           --                                                               --           --             --      158   −2.56 (2.14)   79    −1.18 (2.06)   −1.38
   67--89                                                           --           --                                                               --           --             --      679   −2.05 (2.18)   324   −0.83 (1.77)   −1.22
   \>89                                                             --           --                                                               --           --             --      5     −2.08 (4.35)   2     0.14 (0.20)    −2.22
  Sex                                                                                                                                                                                                                           
   Female                                                           --           --                                                               --           --             --      506   −2.35 (2.32)   231   −1.12 (1.92)   −1.23
   Male                                                             --           --                                                               --           --             --      478   −1.81 (2.07)   245   −0.91 (1.82)   −0.89

**Notes:**

Pooled placebo patients from DPN studies A0081030, A0081071, and A0081081 (DPN);

pooled placebo patients from DPN studies 1008-014,1008-029, 1008-040, 1008-131, 1008-149, 1008-155 (DPN), A0081060, and A0081163;

mean change (SD) from baseline in pain score at endpoint;

pooled placebo patients from PHN studies 1008-030, 1008-045, 1008-127, 1008-155 (PHN), 1008-196, A0081004, and A0081081 (PHN).

**Abbreviations:** DPN, diabetic peripheral neuropathy; PHN, postherpetic neuralgia; SD, standard deviation; y, years.

###### 

Univariate predictors of change in pain at endpoint in the placebo population across all studies for categorical variables: being female, higher active treatment:placebo ratio, and studies conducted postapproval are significantly associated with a higher placebo response

  Variable                                                               DPN   PHN                                            
  ---------------------------------------------------------------------- ----- -------------- ---------- ----- -------------- --------
  Sex                                                                                         \<0.0001                        0.0016
   Female                                                                466   −1.85 (2.22)              231   −1.12 (1.92)   
   Male                                                                  572   −1.64 (2.11)              245   −0.91 (1.82)   
  Site recruitment[b](#tfn28-jpr-8-257){ref-type="table-fn"}                                  \<0.0001                        0.0036
   ≤5                                                                    735   −1.65 (2.10)              367   −1.02 (1.87)   
   6--8                                                                  231   −1.99 (2.41)              91    −1.07 (1.90)   
   9--11                                                                 40    −1.63 (1.84)              18    −0.65 (1.69)   
   ≥12                                                                   32    −1.99 (1.91)              --    --             
  Pregabalin approval status[c](#tfn29-jpr-8-257){ref-type="table-fn"}                        \<0.0001                        0.0028
   Preapproval                                                           467   −1.47 (2.11)              361   −0.85 (1.88)   
   Postapproval                                                          571   −1.95 (2.18)              115   −1.52 (1.75)   
  Enrollment period[d](#tfn30-jpr-8-257){ref-type="table-fn"}                                 \<0.0001                        0.0136
   1st quartile                                                          224   −1.56 (2.15)              46    −0.94 (1.94)   
   2nd quartile                                                          218   −1.77 (2.29)              129   −0.99 (1.87)   
   3rd quartile                                                          263   −2.03 (2.18)              136   −0.98 (1.83)   
   4th quartile                                                          333   −1.60 (2.05)              165   −1.08 (1.90)   
  Ratio of active:control[e](#tfn31-jpr-8-257){ref-type="table-fn"}                           \<0.0001                        0.0028
   1:1                                                                   287   −1.26 (1.96)              84    −1.10 (2.03)   
   ≥2:1                                                                  751   −1.92 (2.21)              392   −0.99 (1.84)   
  Sites per study, n                                                                          \<0.0001                        0.0028
   10--26                                                                222   −1.55 (2.04)              116   −1.22 (1.96)   
   27--42                                                                82    −1.18 (1.80)              186   −1.30 (1.79)   
   43--49                                                                357   −1.88 (2.29)              81    −0.48 (1.65)   
   50--76                                                                377   −1.82 (2.16)              93    −0.63 (1.95)   

**Notes:** *P*-value based on Student's *t*-test;

mean change (SD) from baseline in pain score at endpoint in the pooled placebo arms;

number of patients recruited at each site;

pregabalin approval status at the commencement of the study;

point of patient enrollment into the study relative to full study population;

ratio of the total number of patients receiving active treatment to patients receiving placebo.

**Abbreviations:** DPN, diabetic peripheral neuropathy; PHN, postherpetic neuralgia; SD, standard deviation.

###### 

Univariate predictors of change in pain at endpoint in the placebo population across all studies for continuous variables: younger age, shorter duration of PHN, higher baseline pain score, and longer study duration are significantly associated with a higher placebo response

  Variable               DPN     PHN                                                      
  ---------------------- ------- --------- --------- ---------- ----- --------- --------- --------
  Age                    1,038   0.05462   0.0138    0.0262     476   0.06461   0.0283    0.0007
  Duration of NeP        627     0.03579   −0.0006   0.9830     --    --        --        --
  Duration of diabetes   685     0.02435   −0.0014   0.8697     --    --        --        --
  Duration of DPN        367     0.04232   −0.0068   0.8153     --    --        --        --
  Duration of PHN        --      --        --        --         476   0.05975   0.0070    0.0028
  Baseline pain score    1,038   0.09065   −0.2895   \<0.0001   476   0.04249   −0.0375   0.5039
  Study duration         1,038   0.11660   −0.1958   \<0.0001   476   0.06967   −0.1226   0.0002

**Notes:** Not all studies recorded duration of illness; *P*-values based on Student's *t*-test;

β represents the change from baseline to endpoint in daily pain rating scale score associated with a one-unit change in the continuous variable; A negative β implies each unit in the continuous variable is associated with a greater improvement in pain score with placebo.

**Abbreviations:** DPN, diabetic peripheral neuropathy; NeP, diabetic neuropathic pain; PHN, postherpetic neuralgia.
